<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/793D4069-FC5E-42AF-B620-ABF6BF45C37B"><gtr:id>793D4069-FC5E-42AF-B620-ABF6BF45C37B</gtr:id><gtr:name>Endomagnetics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/793D4069-FC5E-42AF-B620-ABF6BF45C37B"><gtr:id>793D4069-FC5E-42AF-B620-ABF6BF45C37B</gtr:id><gtr:name>Endomagnetics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EA3452E5-C1F4-4C6B-AF8B-5D7F74F42B44"><gtr:id>EA3452E5-C1F4-4C6B-AF8B-5D7F74F42B44</gtr:id><gtr:firstName>Jacqueline</gtr:firstName><gtr:surname>Shields</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12022%2F5"><gtr:id>365FEE79-3BDD-4E2F-8D3C-5188A569DDB9</gtr:id><gtr:title>Defining stroma function in the developing tumour microenvironment</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12022/5</gtr:grantReference><gtr:abstractText>Our immune system is our primary defence mechanism, but tumours have developed strategies to interfere with almost every step necessary for our immune system to recognise and destroy cancer cells. The recent success of immunotherapy, which aim to ?kick start? our immune system hold great promise, but currently are effective in just a few cancer types, with many patients not responding. Understanding how a tumour is able to evade and switch off our immune system during its development will be key to the development of improved treatments and the design of new, targeted therapies. A tumour contains many non-cancer cells that are critical to support the tumour as it develops. One of these populations, the cancer associated fibroblast, is emerging as a key promoter of tumour inflammation, but little is known about the how, when or who they act upon in a tumour, or how they prevent therapies from working. This programme uses state-of-the-art technologies to address these problems. Using such an integrative approach we aim to uncouple the networks governing the suppressive function of cancer-associated fibroblasts, and to exploit these findings to develop new or improved approaches to cancer therapy.</gtr:abstractText><gtr:technicalSummary>Our immune system is our primary defence mechanism destroying both exogenous and endogenous threats, but tumours have developed strategies to interfere with almost every step necessary for a successful anti-tumour immune response. The recent success of immunotherapy platforms to harness and reactivate the immune response represent a major therapeutic advancement, however, current approaches are effective in just a few cancer types, and many patients still fail to respond or do not see lasting benefits. Increasing our understanding of anti-tumour immunity and the suppressive networks at play during the different stages of malignant transition will be fundamental to the development of improved strategies and design of new, targeted therapeutic platforms. The supporting tumour stroma, particularly cancer associated fibroblasts (CAFs) are emerging as key sources of tumour-promoting inflammation, but little is known about the mechanisms by which these cells act, when in tumour evolution these functions are acquired, or how they may contribute to therapeutic resistance. This programme takes a multidisciplinary approach, integrating experimental cancer models, complex in vitro and in silico systems, high throughput genomics and bioinformatics to explore the mechanisms and evolution of stromal-mediated immune dysfunction in the tumour microenvironment. Focusing on a subset of CAFs and their counterparts at tumour draining lymph nodes, which express the glycoprotein podoplanin, we aim to uncouple the immunoregulatory systems governing their suppressive function.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1794000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>EMBL European Bioinformatics Institute (EMBL - EBI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Immune cell mediated steroidogenesis - single cell sequencing</gtr:description><gtr:id>54AA0D6F-E028-496D-9310-0117102D0837</gtr:id><gtr:impact>Ongoing project</gtr:impact><gtr:outcomeId>56dd8a51d80591.34439418-1</gtr:outcomeId><gtr:partnerContribution>Providing expertise on steroidogenesis, single cell sequencing platform and intellectual input. Co-investigator on Cancer Research UK Tumour Immunology Grant</gtr:partnerContribution><gtr:piContribution>We are proving tumour biology expertise, in vivo experimental approaches and intellectual input. Co-investigator on Cancer Research UK Tumour Immunology Grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Cancer Unit</gtr:department><gtr:description>Modelling stromal function in tumour draining lymph nodes</gtr:description><gtr:id>BF0AE09B-5260-4E1E-B8F4-27DBEFE68F0B</gtr:id><gtr:impact>Riedel et al Nature Immunology 2016. This is a multidisciplinary collaboration crossing wet lab and in silica approaches</gtr:impact><gtr:outcomeId>58c13b1cd902f8.74864241-1</gtr:outcomeId><gtr:partnerContribution>This a collaboration between computational biologists and wet lab experimentalists. We have performed experiments yielding large amounts of data that was analysed by them. Data from their was then used as a basis for their modelling systems, where their predictions were functionally verified by members of my lab</gtr:partnerContribution><gtr:piContribution>This a collaboration between computational biologists and wet lab experimentalists. We have performed experiments yielding large amounts of data that was analysed by them. Data from their was then used as a basis for their modelling systems, where their predictions were functionally verified by members of my lab</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Endomagnetics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lymphatic function</gtr:description><gtr:id>417226F1-C86E-4D0E-829F-8FD675F063DF</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>rs5adNQVzsK-1</gtr:outcomeId><gtr:partnerContribution>Provision of research materials and intellectual input</gtr:partnerContribution><gtr:piContribution>Providing mechanistic insight into function of research product based upon the expertise and models available within the research group</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Nutrition Research Unit</gtr:department><gtr:description>anti-timor effects of Nanosilica preprations</gtr:description><gtr:id>7B71B8A0-EB37-46FE-9DC2-87E6DE8DDB0E</gtr:id><gtr:impact>Still ongoing</gtr:impact><gtr:outcomeId>56dd88a27fbdd5.44816171-1</gtr:outcomeId><gtr:partnerContribution>They are providing novel formulations, expertise on immunology and intellectual input</gtr:partnerContribution><gtr:piContribution>We are providing expertise and experimental approaches/reagents relating to tumor biology and tumor immunology, and intellectual input</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge Science Festival 2014</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EDC0EB6F-1E84-42A9-8384-8FE4312654A8</gtr:id><gtr:impact>Spoke to public about research and coordinated activities about the cell matrix

Increased awareness of research</gtr:impact><gtr:outcomeId>543e527b1066f3.22199806</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in MRC Festival of Science Open Day 2016 at MRC CU</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AE6A99AE-D983-4741-8157-A4093547053E</gtr:id><gtr:impact>60 sixth-form students from across 8 schools in Cambridge visited the MRC Cancer Unit on the afternoon of the 22nd of June, 2016 for an Open Day. All students, accompanied by their teachers, were given a tour of the enitre building with an opportunity for engaging with researchers about the state of the art in cancer research and gaining hands-on experience with setting up experiments. Talks about career opportunities and challenges associated with pursuing cancer research were also available to all attendees. The event sparked a great deal of interest and enthusiasm in students and teachers alike and we have had a request for this event to be continued. We will be pursuing a similar format of activities for the MRC Science Festival in 2017, but reach out to more number of schools, including those outside of Cambridge city perimeters.</gtr:impact><gtr:outcomeId>58a336a8486c44.23435514</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://mrccancerunit.wordpress.com/2016/07/06/inspiring-the-next-generation-of-cancer-researchers-the-mrc-cancer-unit-open-day-2016/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in Cambridge University Science Festival (2015-2016)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DFB4142A-DEEC-4303-A49C-8D4B70A7BAC0</gtr:id><gtr:impact>The Cambridge Science Festival, organised to coincide with the National Science week, aims to reach out to the general public and communicate about the different aspects of science and research being undertaken at the University. It is a free event, over two weeks, with an excess of 270 events and more than 30000 attendees. As part of this festival, the MRC CU along with the CRUK CI organised a set of talks and activities that were attended by over 100 people from all walks of life - from young children and young adults to parents/carers and professionals. The Shields lab was part of the MRC CU team at this event. Overall, the event generated a lot of interest in cancer research, helped raise awareness about the importance of 'early' in cancer which is the mission of the MRC CU and also led to a lot of interest being generated in the MRC Festival of Science which followed on later in the year.</gtr:impact><gtr:outcomeId>58a337f5daa5f2.37776841</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencefestival.cam.ac.uk</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28443</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Endomagnetics - Longitudinal Study</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Endomagnetics</gtr:fundingOrg><gtr:id>7E8C0FC3-9F03-494D-82DC-28D499EF9DE8</gtr:id><gtr:outcomeId>56d59199ce4681.84707836</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>655CD418-2F2A-4909-A43C-D2785F331D45</gtr:id><gtr:title>Cancer-associated fibroblasts induce antigen-specific deletion of CD8T Cells to protect tumour cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/554901e2773ad5713f0aee759e7d6cd4"><gtr:id>554901e2773ad5713f0aee759e7d6cd4</gtr:id><gtr:otherNames>Lakins MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa1068dc490a7.71390767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57F53687-76E2-442D-828C-84F533640CC6</gtr:id><gtr:title>Tumor-induced stromal reprogramming drives lymph node transformation.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af423ffadeab65aec57c9a09110810cd"><gtr:id>af423ffadeab65aec57c9a09110810cd</gtr:id><gtr:otherNames>Riedel A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>58a335e2339f09.81525021</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12022/5</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>